RPG Life Sciences Limited (IN:RPGLIFE)
:RPGLIFE
Want to see IN:RPGLIFE full AI Analyst Report?
RPGLIFE Stock Chart & Stats
₹2303.55
-₹26.05(-1.12%)
At close: 4:00 PM EST
₹2303.55
-₹26.05(-1.12%)
Day’s Range― - ―
52-Week Range₹1,731.25 - ₹2,715.90
Previous CloseN/A
Volume11.08K
Average Volume (3M)3.23K
Market Cap
₹37.59B
Enterprise Value₹36.36B
Total Cash (Recent Filing)₹2.24B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)32.7
Beta0.80
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.85%
Share Statistics
EPS (TTM)130.26
Shares Outstanding16,539,015
10 Day Avg. Volume8,652
30 Day Avg. Volume3,228
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)5.08
Price to Sales (P/S)4.34
P/FCF Ratio-38.40K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a conservatively positioned balance sheet give durable financial flexibility. Over the next 2-6 months this supports funding of working capital, R&D or selective capex without stressing liquidity, and provides buffer versus industry volatility or regulatory shifts.
Steady Revenue GrowthConsistent mid-to-high single digit revenue growth reflects resilient demand for branded formulations and repeat prescription dynamics. This steady top-line trend indicates durable market position in domestic prescription channels and underpins medium-term cash generation prospects.
Historically Strong ROESustained high ROE historically indicates effective capital allocation and a profitable business model versus peers. Even with some easing, elevated ROE supports reinvestment capacity and suggests the firm earns attractive returns on assets, a durable competitive strength over months.
Bears Say
FY2026 Margin CompressionA clear step-down in margins reduces sustainable profitability and free cash generation. If driven by structural cost pressures or pricing erosion, this can linger beyond a quarter, constraining reinvestment, squeezing operating leverage, and making earnings more sensitive to volume swings.
Weakened Cash ConversionMaterial deterioration in cash conversion and a shift to slightly negative free cash flow undermines liquidity resilience. Persisting higher working-capital needs or elevated capex could force external financing or reduce strategic flexibility in the medium term, raising execution risk.
Sharp EPS DeclineA large negative EPS growth reading signals notable earnings volatility and weaker near-term profitability. Over a multi-month horizon this can reflect structural margin or cost issues and may limit retained earnings available for reinvestment or shareholder returns until recovery is proven.
RPG Life Sciences Limited News
RPGLIFE FAQ
What was RPG Life Sciences Limited’s price range in the past 12 months?
RPG Life Sciences Limited lowest stock price was ₹1731.25 and its highest was ₹2715.90 in the past 12 months.
What is RPG Life Sciences Limited’s market cap?
RPG Life Sciences Limited’s market cap is ₹37.59B.
When is RPG Life Sciences Limited’s upcoming earnings report date?
RPG Life Sciences Limited’s upcoming earnings report date is Jul 24, 2026 which is in 33 days.
How were RPG Life Sciences Limited’s earnings last quarter?
RPG Life Sciences Limited released its earnings results on Apr 29, 2026. The company reported ₹18.08 earnings per share for the quarter, beating the consensus estimate of N/A by ₹18.08.
Is RPG Life Sciences Limited overvalued?
According to Wall Street analysts RPG Life Sciences Limited’s price is currently Overvalued.
Does RPG Life Sciences Limited pay dividends?
RPG Life Sciences Limited pays a Notavailable dividend of ₹24 which represents an annual dividend yield of 0.85%. See more information on RPG Life Sciences Limited dividends here
What is RPG Life Sciences Limited’s EPS estimate?
RPG Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RPG Life Sciences Limited have?
RPG Life Sciences Limited has 16,539,015 shares outstanding.
What happened to RPG Life Sciences Limited’s price movement after its last earnings report?
RPG Life Sciences Limited reported an EPS of ₹18.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.761%.
Which hedge fund is a major shareholder of RPG Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:RPGLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RPG Life Sciences Limited
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs) for both the Indian and global markets. The company provides synthetic APIs for diverse medical applications, including immunosuppression, psychiatric conditions, cardiac health (anti-anginals), parasitic infections (anthelmentics), seizure management (anticonvulsants), and muscle spasm relief (antispasmodics). While its generics portfolio primarily centers on immunosuppressant treatments, its finished dosage formulations address a wide spectrum of therapeutic areas, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular health, diabetology, orthopedics, neuropsychiatry, and respiratory conditions, among many others. Established in 1968 with its headquarters in Mumbai, India, the company adopted its current name in February 2008, having previously been known as RPG Pharmaceuticals Limited. RPG Life Sciences Limited functions as a subsidiary of Nucleus Life Trust.
Technical Analysis
Bliss Gvs Pharma Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―